Compare Illumina, Inc. (ILMN) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Live Nation Entertainment, Inc. — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Live Nation Entertainment, Inc. trades at $183.14 (market cap $43.01B). The key difference: Live Nation Entertainment, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ILMN | LYV | |
|---|---|---|
Market Cap | $28.96B | $43.01B |
Sector | Health | Industrials |
52-Week High | $205.10 | $186.59 |
52-Week Low | $91.00 | $125.61 |
Enterprise Value | $30.32B | $45.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Live Nation (LYV) trades at $180.66, down 0.61% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $209.54. The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by strong concert demand. However, valuation metrics like a P/E of 117.49 and a P/B of 511.19 appear elevated, while net income margin remains thin at 0.51% for 2025.
The outlook is supported by robust fan attendance and raised full-year expectations, but risks include high debt levels, legal uncertainties, and cost pressures. With 87% of analysts rating it a buy, the stock offers growth potential contingent on execution amid competitive and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
